News | April 07, 2025
Sun Pharma introduces Fexuclue in India for treatment of Erosive Esophagitis
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Subscribe To Our Newsletter & Stay Updated
